Breaking Finance News

Clearside Biomedical Inc (NASDAQ:CLSD) has been upgraded to Hold in a statement by Zacks Investment Research earlier today.

Having a price of $24.72, Clearside Biomedical Inc (NASDAQ:CLSD) traded 5.49% higher on the day. With the last stock price up 118.47% from the two hundred day average, compared with the Standard & Poor's 500 Index which has decreased -0.01% over the same period. CLSD has recorded a 50-day average of $13.38 and a two hundred day average of $9.23. Trade Volume was down over the average, with 53,743 shares of CLSD changing hands under the typical 85,654

Zacks Investment Research has upgraded Clearside Biomedical Inc (NASDAQ:CLSD) to Hold in a statement released on Tuesday October 11, 2016.

Recent Performance Chart

Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical Inc has with a one year low of $5.65 and a one year high of $25.08 and has a total market value of $0.

A total of 3 brokerages have issued a ratings update on the company. 0 analysts rating the company a strong buy, zero firms rating the stock a buy, 0 equity analysts rating the company a hold, 0 brokers rating the stock a underperform, and finally zero brokerages rating the company a sell with a 12-month stock price target of $19.00.

Brief Synopsis On Clearside Biomedical Inc (NASDAQ:CLSD)

Clearside Biomedical, Inc. is a late-stage clinical biopharmaceutical company. The Company is developing drug therapies to treat blinding diseases of the eye. The Company's product candidates are focused on diseases affecting the retina and choroid, especially diseases associated with macular edema, and are injected into the suprachoroidal space (SCS) adjacent to the choroid, using its SCS Microinjector. With the SCS injection, its product candidates are directly administered to the retina and choroid. Its product candidates are CLS-1001, CLS-1003 and CLS-1002. CLS-1001 and CLS-1003 are based on commonly used ophthalmic drugs. Its CLS-1001 program is being developed for the treatment of macular edema associated with non-infectious uveitis. CLS-1001 consists of an SCS injection of Zuprata, its preservative-free formulation of the corticosteroid triamcinolone acetonide (TA), specifically designed to be administered through its SCS Microinjector.

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with's FREE daily email newsletter.

Leave a Reply

Your email address will not be published. Required fields are marked *